Prostate brachytherapy can be used as a monotherapy for low- and intermediate-risk patients or in combination with external beam radiation therapy (EBRT) as a form of dose escalation for selected intermediate- and high-risk patients.
Prostate brachytherapy with either permanent implants (low dose rate [LDR]) or temporary implants (high dose rate [HDR]) is emerging as the most effective radiation treatment for prostate cancer. Several large Canadian brachytherapy programs were established in the mid- to late-1990s. Prostate brachytherapy is offered in British Columbia, Alberta, Manitoba, Ontario, Quebec and New Brunswick. We anticipate the need for brachytherapy services in Canada will significantly increase in the near future. In this review, we summarize brachytherapy programs across Canada, contemporary eligibility criteria for the procedure, toxicity and prostate-specific antigen recurrence free survival (PRFS), as published from Canadian institutions for both LDR and HDR brachytherapy.
Written by:
Keyes M, Crook J, Morris WJ, Morton G, Pickles T, Usmani N, Vigneault E. Are you the author?
Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC.
Reference: Can Urol Assoc J. 2013 Jan-Feb;7(1-2):51-8.
doi: 10.5489/cuaj.218
PubMed Abstract
PMID: 23671495
UroToday.com Prostate Cancer Section
